Drugs and Devices

FDA approves Promacta for pediatric patients with chronic ITP

On Aug. 24, the U.S. Food and Drug Administration (FDA) approved Promacta (eltrombopag) to treat chronic immune thrombocytopenic purpura (ITP) in pediatric patients (ages one year and older). Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares